Drug
Omiganan pentahydrochloride clinical trials
Also written CLS001.
- studies test it
- 11
- open now
- 0
- in phase 3
- 3
- first study started
- 2000
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2003 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Maruho Co., Ltd. (8) · BioWest Therapeutics Inc (3)
Studies
Open first, then newest update. How each study uses omiganan pentahydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus VehicleCompletedPhase 3Maruho Co., Ltd.NCT02576860Written as CLS001 (Omiganan)
- Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus VehicleCompletedPhase 3Maruho Co., Ltd.NCT02547441Written as CLS001 (Omiganan)
- Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVINCompletedPhase 2Maruho Co., Ltd.NCT02596074Written as Omiganan (CLS001) topical gel
- Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital WartsCompletedPhase 2Maruho Co., Ltd.NCT02849262Written as Omiganan (CLS001) topical gel
- A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne VulgarisCompletedPhase 2Maruho Co., Ltd.NCT02571998Written as Omiganan (CLS001) Topical Gel
- Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic DermatitisCompletedPhase 2Maruho Co., Ltd.NCT02456480Written as CLS001
- Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne VulgarisCompletedPhase 2Maruho Co., Ltd.NCT02066545Written as CLS001 Topical Gel
- A 21 Day Pharmacokinetics Study in Papulopustular RosaceaCompletedPhase 1Maruho Co., Ltd.NCT02028286Written as CLS001
- Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of AcneCompletedPhase 2BioWest Therapeutics IncNCT00211523Written as MBI 226 Acne Solutions
- Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of AcneCompletedPhase 2BioWest Therapeutics IncNCT00211497Written as MBI 226 Acne Solutions
- Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream InfectionsCompletedPhase 3BioWest Therapeutics IncNCT00027248Written as MBI 226
Codes
What other systems call omiganan pentahydrochloride · ClinicalTrials.gg INT004577
- MeSH (NLM) C478918omiganan pentahydrochlorideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LX2P9RD54VOMIGANAN PENTAHYDROCHLORIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q72497841Omiganan pentahydrochlorideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91016Omiganan PentahydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C478918 | omiganan pentahydrochloride | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LX2P9RD54V | OMIGANAN PENTAHYDROCHLORIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q72497841 | Omiganan pentahydrochloride | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91016 | Omiganan Pentahydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.